DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

NCT02744053 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Triple-Negative Breast Carcinoma

Interventions

PROCEDURE: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
OTHER: Laboratory Biomarker Analysis
RADIATION: Scintimammography
DRUG: Technetium Tc-99m Sestamibi

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]